GN Audio

GN Store Nord is the Danish double-helix that confused every analyst between 2021 and 2024 — a hearing-aid business (ReSound) glued to a headset/audio business (Jabra) with almost zero operational overlap. The market punished the conglomerate discount for three straight years, then rewarded the spin-out logic when management announced the Jabra Enterprise (Speak/PanaCast/headset) divestiture to Lenovo in October 2025 for DKK 8.4 bn cash. What is left after closing in H2/2026 is a focused medical-grade hearing-aid pure-play with a small Jabra-Consumer Earbud sleeve attached.

The core thesis sits on the Nexia platform — ReSound's first fully Bluetooth-LE/Auracast-native hearing-aid chip, launched March 2025 and now in over 11.000 European audiologist clinics. Audiograph-quality independent reviews put Nexia in the top quartile against Phonak Sphere, Oticon Intent and Starkey Edge AI; the differentiator is battery life (30h+) and a 17g earhook that the over-70 segment actually keeps on all day.

The macro tailwind: WHO estimates 466 M people globally with disabling hearing loss, of which only ~17% currently use a hearing aid. EU MDR-2024 reimbursement reforms in Germany, France and Italy lifted the per-fitting payout 8-12% in 2025 — direct margin uplift for ReSound's wholesale channel.

Institutional ownership is tilted European/Scandinavian: William Demant Invest (the family foundation behind direct competitor Demant) held a passive 4.9% as of Q1/2026 — a strange but persistent position. ATP (Danish pension giant) at 5.1%, Norges Bank at 3.4%, BlackRock 3.1%. No US activist of size; Engaged Capital exited fully in Q4/2025 after the Lenovo deal was confirmed.

The insider signal is mixed. Chairman Anders Boyer-Søgaard bought DKK 2.1 M in February 2026 at DKK 85-88 — first open-market purchase in two years. CEO Peter Karlstromer (joined June 2025 from Sonova) has not bought yet but the equity grant structure forces him to accumulate to 5x salary by 2028. CFO Søren Jelert sold DKK 4 M post the Lenovo deal close-announcement at DKK 99 — measured profit-taking, not a dump.

Short interest is unusual: 6.8% short of float in May 2026, mostly tied to the spread-trade against Demant (long Demant / short GN). If Nexia gains share in Q2 earnings, the squeeze risk is real.

Pre-deal-close optics distort everything: trailing P/E of 52.5x is on a depressed Jabra-Consumer earnings base. The clean view is forward P/E 15.6x on a hearing-aid-only GN, vs Demant 19.4x and Sonova 22.1x. EV/EBITDA forward 9.8x against peers at 13-15x. PEG of 1.17 reflects 13% expected EPS growth — conservative given the Lenovo capital return. SEB sees fair value at DKK 130-145 (peer-multiple re-rate), Carnegie at DKK 125, Goldman at DKK 118. Mean analyst target DKK 114 (+21% upside) likely lifts after Q2/2026 confirms Nexia traction. Note: in EUR the math is cleaner — DKK denomination makes the multiple look optically harsher than it is.

1. Q2 2026 earnings (August): First clean print showing Nexia EU share gains + initial Lenovo-deal sale proceeds; consensus is +12-14% organic ReSound growth
2. H2 2026 close: Jabra Enterprise to Lenovo transaction closes; DKK 8.4 bn lands and accelerated buyback program starts
3. Q3 2026 strategy day: Karlstromer presents Hearing-Aid-only GN long-term plan; market grades capital allocation discipline (buyback pace + Jabra Consumer fate)

GN Store Nord is the cleanest re-rating setup in European medtech for 2026 — but you have to believe two things at once. First, that the Lenovo cash actually lands (transaction-close risk is low, but Chinese-buyer regulatory review in Brussels is non-zero). Second, that Nexia keeps gaining share against Sonova's Sphere through 2026. If both hold, you get the pure-play multiple uplift and the operating beat — that compounding is what makes the asymmetry. I would size this 2-3% of equity with a stop at DKK 78 (below the chairman insider buy), planning to add 100 bp on a clean Q2 print. The Jabra Consumer drag is the part I dislike most — but Karlstromer has the credibility to euthanize it, and Q3 strategy day is the right venue.